FDA Clarifies Certification Requirement - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

FDA Clarifies Certification Requirement

ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Rockville, MD (Apr. 21)—The US Food and Drug Administration issued a draft guidance to clarify the agency’s intentions stated in the Food and Drug Administration Amendments Act of 2007 (FDAAA) requiring sponsors, industry, researchers, and investigators to complete certification form FDA 3674 when submitting documentation to the agency in order to comply with FDAAA, Title VIII.

FDA's Draft Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff was created in response to questions FDA has received about which documents and information should include the certification form. FDA states in the draft guidance that the agency “believe(s) that it would not further the purposes of the legislation if a certification were to accompany every type of information or document submitted to the agency regarding a medical product regulated by FDA.” The guidance goes on to state “FDA recommends that a certification typically need not accompany the types of submissions of information or documents to the agency listed below:

Investigational applications/submissions

  • Chemistry and manufacturing amendments to investigational new drug applications (INDs)
  • Nonclinical pharmacology/toxicology amendments to INDs
  • IND safety reports
  • Single patient INDs
  • Meeting requests
  • Investigational device exemption applications (IDEs)

Marketing and post-marketing applications/submissions

  • Chemistry and manufacturing amendments and supplements to biologics license applications (BLAs) and new drug applications (NDAs)
  • Nonclinical pharmacology/toxicology amendments and supplements to BLAs and NDAs
  • Humanitarian device exemptions (HDEs) and premarket approval application (PMA) 30 day notices
  • ANDA amendments and supplements that contain no in-vivo bioequivalence information
  • ANDA, BLA, and NDA promotional materials
  • BLA and NDA safety reports
  • ANDA, BLA, NDA, HDE, and PMA mandatory and voluntary adverse event or medical device reports
  • Meeting requests
  • 510(k)s that contain no clinical data.”

Click here to download the draft guidance.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here